Nanjing, China, November 28th, 2020--TransThera Biosciences announces today the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of TT-00420 for the indication of cholangiocarcinoma (CCA), upon which TransThera will initiate Phase 2 clinical trial in 2021 to evaluate the efficacy and safety of TT-00420 in CCA patients.
Nanjing TransThera Biosciences Co., Ltd. today announced the presentation of preclinical data on TT-00920, the company’s clinical stage Phosphodiesterase 9 (PDE9) inhibitor, at the American Heart Association (AHA) Scientific Sessions 2020, taking place online from November 13-17, 2020. The data demonstrated that in preclinical chronic heart failure model, TT-00920 remarkably improved cardiac function and protected from cardiac remodeling and fibrosis. Compelling preclinical results provide strong evidence that TT-00920 has the potential to be a meaningful new treatment for chronic heart failure.
Nanjing, China, October 29th, 2020--TransThera Biosciences announces today the Investigational New Drug (IND) application of TT-00420 for the indication of cholangiocarcinoma (CCA) has been submitted to Food and Drug Administration (FDA) in the United States.